Prelude Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Prelude Therapeutics Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Prelude Therapeutics is asking stockholders to approve an amendment to its restated certificate of incorporation to increase the number of authorized non-voting common shares, providing greater flexibility for future business needs.
NASDAQ
Prelude Therapeutics Incorporated files a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
Prelude Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to elect directors and ratify the appointment of its independent accounting firm.